CancerLivER: Biomarker Card

Biomarker Card: Comprehensive information about a biomarker


Biomarker ID 2484
Detailed information
CancerLivER ID2484
Biomarker SOX6, ITIH4, HDGF, SKIP1, RBP4, LOC92033, UGT2B7, FABP1, GATM, UQCRC1, UK114, CP, PBEF, KAL1, CES2, GPX4, UGT1A4, RCL, PABPC1, EST, FGA, RARRES2, SLC22A, SRP14, FLJ14294, cyclin, CA2, CLDN1, FTL, FLJ10004, CYP3A5, ARHGEF12, TDO2, NDUFB2, TEGT, SPR, PCK2, MGC13114, EST, MTHFS, F2, FLJ22313, C9orf5, H
Biomarker Name/Symbol (given in Publication)159 gene signature (SOX6, ITIH4, HDGF, SKIP1, RBP4, LOC92033, UGT2B7, FABP1, GATM, UQCRC1, UK114, CP, PBEF, KAL1, CES2, GPX4, UGT1A4, RCL, PABPC1, EST, FGA, RARRES2, SLC22A, SRP14, FLJ14294, cyclin, CA2, CLDN1, FTL, FLJ10004, CYP3A5, ARHGEF12, TDO2, NDUFB2, TEGT, SPR, PCK2, MGC13114, EST, MTHFS, F2, FLJ22313, C9orf5, HFL3, MPST, EST, FLJ20287, UQCRFS1, SERPINA5, ARAP3, PPP1R1A, FLJ10847, CBS, RAB7, HAGH, AFM, PON3, SLC38A3, CALP, GMFG, HSPC039, ATP5H, ARF6, EST, HSPC154, UBAP1, KIAA1458, EST, FACL4, CENPE, HBSAA, EIF2B3, PTEN, DPP9, CAPN2, SMBP, STAM, EST, NOLA1, VDAC2, HSBP1, FLJ12960, TAP1, DVL1, MAP3K5, P53, MGC1223, FLJ32072, NP220, BCL2L1, HSPC125, PRKX, EST, G1P3, FLJ20686, TSC1, KIAA1915, MURR1, CTBS, PUM2, EST, FLJ21252, KIAA0872, SDCCAG8, MID2, CRL2, FMR1, FLJ12687, KIAA0738, FLJ23566, EVIN1, EST, GSN, FLJ22806, LTB4R2, MTCH1, AD7C-NTP, NDUFS8, HSPG2, DUSP1, POLR2B, UBE2G2, LGALS3BP, FLJ37818, FLJ21503, KIAA1052, MRPS21, COL1A1, FLJ20489, CTSB, KIAA1833, RHCE, PEPD, PRG4, ACOX2, SLC27A2, SUCLG2, AOP2, FLJ10006, SELENBP1, HFL1, TMPIT, WAC, ORM1, DMR, RABEX5, CYP3A4, APOA1, WBSCR14, FLJ36984, MGC15937, DIO1, C9, FH, SURB7, CYP2B6, SERPINA4, BCHE, TOM1)
BiomoleculeRNAs
SubjectHuman
Degree of ValidityPotential Diagnostic marker for HCC and validated on independent dataset
Experimental ConditionHCC v/s normal
Cancer typeHepatocellular carcinoma
RegulationDifferentially expressed between HCC and normal tissues
Level of significance p < 0.01
SourceTissue
PMID14642619
Type of BiomarkerDiagnostic
PathwayNA
CohortTraining dataset: 68 non-B, non-C liver samples, including 20 T and 17 NT samples, that were obtained from non-B, non-C HCC patients, and 31 N samples from metastatic liver cancer patients; Validation dataset: 37 non-B, non-C liver tissues (20 HCC, 17 non-tumor liver) from 20 patients
SensitivityNA
SpecificityNA
Accuracy93.30%
AUC
DiseaseHCC v/s normal
Year of Publication2003
Clinical trialNO
Clinical trial (NCT Number)NA

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top